Physician profile
Keshav Narain
NPI 1487680328
$10,962.29
in general payments reported to CMS, 2019-2025
30 companies · $3,410 in 2025
The $3,410 reported for 2025 was more than what 86% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $308 · 2021: $709 · 2022: $1,943 · 2023: $1,605 · 2024: $2,462 · 2025: $3,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,084 · Travel and Lodging: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,084.32 |
| Travel and Lodging | $393.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $3,563.53 | 2021-2025 | |
| Amgen INC. | $1,070.49 | 2024-2025 | Tepezza, Pavblu |
| Sun Pharmaceutical Industries INC. | $1,000.18 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Alcon Vision LLC | $646.66 | 2022-2025 | Rocklatan, Tryptyr, Rhopressa |
| Oyster Point Pharma, INC. | $620.05 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $546.45 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $519.02 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $441.72 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $343.55 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $315.08 | 2023-2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $289.32 | 2020-2022 | |
| Carl Zeiss Meditec USA, INC. | $258.58 | 2022-2025 | |
| Allergan, INC. | $217.88 | 2019-2021 | |
| Astellas Pharma US INC | $195.83 | 2023-2024 | Izervay |
| Notal Vision, INC. | $172.83 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $145.91 | 2019-2025 | Eylea Hd |
| Dompe US, INC. | $124.99 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.56 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $94.94 | 2019-2022 | |
| Thea Pharma INC. | $48.51 | 2022-2023 | |
| Shire North American Group INC | $39.42 | 2019 | |
| Eyepoint US, INC. | $34.75 | 2022 | |
| Harrow Eye, LLC | $25.45 | 2024 | Vevye |
| Genentech USA, INC. | $24.95 | 2023 | Vabysmo |
| Abbvie INC. | $22.94 | 2022 | |
| Spark Therapeutics, INC. | $21.83 | 2019 | |
| Abiomed | $19.64 | 2021 | |
| Vyera Pharmaceuticals, LLC | $17.23 | 2022 | |
| Alimera Sciences, INC. | $16.18 | 2019 | |
| Viiv Healthcare Company | $13.82 | 2025 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keshav Narain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.